This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/04/2026
The ROCKET AF study was a phase 3, randomized, double-blind, double-dummy, active-controlled, parallel-group, multicenter, event-driven, noninferiority study designed to evaluate the efficacy and safety of XARELTO 20 mg once daily with the evening meal (15 mg once daily with the evening meal in patients with creatinine clearance 30 to <50 mL/min) to warfarin (international normalized ratio, 2 to 3) for the prevention of stroke and systemic embolism (SE) in patients with NVAF at moderate-to-high risk for stroke.34
Patients were included, but not limited to the following in this study34:
| History of Diabetes | P-Value for Interaction | ||||||
|---|---|---|---|---|---|---|---|
| XAR Events/ 100 pt-yrs (Total Events) | Warfarin Events/ 100 pt-yrs (Total Events) | XAR vs Warfarin HR (95% CI) | XAR Events/ 100 pt-yrs (Total Events) | Warfarin Events/ 100 pt-yrs (Total Events) | XAR vs Warfarin HR (95% CI) | ||
| Efficacy Outcomes | |||||||
| SSE | 1.74 (95) | 2.14 (114) | 0.82 (0.63-1.08) | 2.12 (174) | 2.32 (192) | 0.92 (0.75-1.13) | 0.53 |
| Safety Outcomes | |||||||
| Major or nonmajor clinically relevant bleeding | 14.81 (582) | 15.44 (596) | 0.98 (0.88-1.1) | 14.99 (893) | 13.94 (853) | 1.09 (0.99-1.2) | 0.17 |
| Major bleeding | 3.79 (165) | 3.9 (169) | 1 (0.81-1.24) | 3.47 (230) | 3.17 (217) | 1.12 (0.93-1.35) | 0.43 |
| Hemorrhagic stroke | 0.23 (10) | 0.46 (20) | 0.51 (0.24-1.09) | 0.28 (19) | 0.43 (30) | 0.65 (0.37-1.16) | 0.61 |
| Intracranial hemorrhage | 0.5 (22) | 0.82 (36) | 0.62 (0.36-1.05) | 0.49 (33) | 0.69 (48) | 0.72 (0.46-1.12) | 0.67 |
| Abbreviations: CI, confidence interval; HR, hazard ratio; pt-yrs, patient-years; SSE, stroke/systemic embolism; XAR, XARELTO. | |||||||
Coleman et al (2018)3 conducted a retrospective, administrative claims database analysis to assess efficacy and safety of XARELTO vs warfarin in patients with NVAF and diabetes treated in routine practice.
Lip et al (2020)4 conducted a retrospective, observational study comparing newly initiated apixaban, dabigatran, XARELTO, or warfarin in diabetic NVAF patients. The study analyzed data from the diabetes subgroup of the ARISTOPHANES study, 4 United States (US) commercial claims databases, and Centers for Medicare and Medicaid Services data to compare SE and major bleeding among a large NVAF population with diabetes. Patients were selected for analysis between January 01, 2013, to September 30, 2015.
| XARELTO vs warfarin | NOAC vs XARELTO |
|---|---|
| 44,412 XARELTO-warfarin | 36,549 apixaban-XARELTO |
| 13,115 dabigatran-XARELTO | |
| Abbreviation: NOAC, non-vitamin K oral anticoagulant. | |
Rates of SSE and major bleeding of XARELTO compared to warfarin are referenced in Table: XARELTO and Warfarin Comparisons.
| Comparator | Reference | Hazard Ratio | P-Value | |
|---|---|---|---|---|
| Incidence rate (per 100 person-years) | (95% CI) | |||
| XARELTO vs Warfarin (ref) | ||||
| SSE | 1.9 | 2.3 | 0.79 (0.71-0.89) | <0.001 |
| Major Bleeding | 7.3 | 7.1 | 1.02 (0.94-1.10) | 0.67 |
| Note: Incidence and hazard ratios of XARELTO vs warfarin. Incidence rates were measured per 100 person-years for matched NOAC cohorts. Hazard ratios were measured along with 95% CIs. Abbreviations: CI, confidence interval; NOAC, non-vitamin K oral anticoagulant; ref, reference; SSE, stroke/systemic embolism. | ||||
| Comparator | Reference | Hazard Ratio | P-Value | |
|---|---|---|---|---|
| Incidence rate (per 100 person-years) | (95% CI) | |||
| Apixaban vs XARELTO (ref) | ||||
| SSE | 1.7 | 1.8 | 0.87 (0.75-1)a | 0.45 |
| Major Bleeding | 4.8 | 7.4 | 0.59 (0.54-0.65) | <0.001 |
| Dabigatran vs XARELTO (ref) | ||||
| SSE | 1.8 | 1.6 | 1.11 (0.85-1.46) | 0.44 |
| Major Bleeding | 4.8 | 6.4 | 0.76 (0.66-0.86) | <0.001 |
| Note: Incidence and hazard ratios of XARELTO vs NOACs. Incidence rates were measured per 100 person-years for matched NOAC cohorts. Hazard ratios were measured along with 95% CIs. Abbreviations: CI, confidence interval; NOAC, non-vitamin K oral anticoagulant; ref, reference; SSE, stroke/systemic embolism. aUpper limit of 95% was rounded from 0.997 to 1.00. | ||||
Coleman et al (2021)5 conducted a retrospective cohort analysis using Optum®
Costa et al (2021)6 conducted a study utilizing Optum de-Identified electronic health record data (November 2010 to December 2019) to evaluate the incidence rate of kidney, limb, and/or ophthalmic complications in patients with NVAF and T2DM newly prescribed XARELTO or warfarin.
Chowdhury et al (2022)7 conducted
| Exposure | No. of Events | PY | Incidence Ratea (95% CI) | Adjusted HRb |
|---|---|---|---|---|
| Stroke | ||||
| XARELTO | 209 | 11,356.82 | 18.4 (16.1-21.1) | 1 (ref) |
| Apixaban | 319 | 13,658.37 | 23.4 (20.9-26.1) | 0.99 (0.79-1.23) |
| Major limb events | ||||
| XARELTO | 108 | 11,389.41 | 9.5 (7.9-11.5) | 1 (ref) |
| Apixaban | 128 | 13,765.61 | 9.3 (7.8-11.1) | 0.75 (0.54-1.04) |
| Major bleeding | ||||
| XARELTO | 607 | 11,097.83 | 54.7 (50.5-59.2) | 1 (ref) |
| Apixaban | 590 | 13,538.84 | 43.6 (40.2-47.2) | 0.68 (0.59-0.78) |
| Abbreviations: CI, confidence interval; HR, hazard ratio; PY, person-years; ref, reference. aPer 1000 PY. bAdjusted using standardized mortality ratio weighting | ||||
Coleman et al (2022)8 conducted a subanalysis of a retrospective study (RIVA-DM) that used data from the Optum® De-Identified electronic health record database from November 2010 to December 2019 to evaluate the impact of age (<80 vs ≥80 years) on the effectiveness and safety of XARELTO vs warfarin in patients with NVAF and T2DM.
| Outcome | Incidence Rate in Patients Aged <80 Years (%/Year) | Incidence Rate in Patients Aged ≥80 Years (%/Year) | |||||
|---|---|---|---|---|---|---|---|
| XARELTO (n=25,472) | Warfarin (n=58,636) | HR (95% CI) | XARELTO (n=6606) | Warfarin (n=25,335) | HR (95% CI) | ||
| Primary outcomes | |||||||
| SSE | 1.15 | 1.21 | 0.95a (0.87-1.04) | 2.08 | 1.98 | 1.05 (0.92-1.19) | |
| Hospitalization for major or CRNMB | 2 | 2.22 | 0.9a (0.84-0.96) | 3.29 | 3.09 | 1.06 (0.96-1.18) | |
| Abbreviations: CI, confidence interval; CRNMB, clinically relevant nonmajor bleeding; HR, hazard ratio; SSE, stroke/systemic embolism. aPinteraction ≥0.23. | |||||||
COMPASS was a phase 3, event-driven, double-blind, randomized, controlled study that compared treatment with XARELTO (2.5 mg twice daily) plus aspirin (100 mg once daily) vs aspirin alone (100 mg once daily) or XARELTO alone (5 mg twice daily) vs aspirin alone (100 mg once daily) in patients with stable CAD or PAD.9
| XAR+Aspirin, n/N (%) | Aspirin Alone, n/N (%) | Hazard Ratio (95% CI) | Interaction P-Value | |
|---|---|---|---|---|
| Composite Endpoint: CV death, stroke, or MI (primary efficacy endpoint) | ||||
| Yes | 179/3448 (5.2) | 239/3474 (6.9) | 0.74 (0.61-0.9) | 0.77 |
| No | 200/5704 (3.5) | 257/5652 (4.5) | 0.77 (0.64-0.93) | |
| Modified ISTH Major Bleeding | ||||
| Yes | 110/3448 (3.2) | 65/3474 (1.9) | 1.70 (1.25-2.31) | 0.97 |
| No | 178/5704 (3.1) | 105/5652 (1.9) | 1.69 (1.33-2.15) | |
| Abbreviations: CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; ISTH, International Society on Thrombosis and Hemostasis; MI, myocardial infarction; XAR, XARELTO. | ||||
Anand et al (2018)37
| Baseline DM | XAR+Aspirin, n/N (%) | Aspirin Alone, n/N (%) | Hazard Ratio (95% CI) | Interaction P-Value |
|---|---|---|---|---|
| Yes | 91/1100 (8) | 128/1104 (12) | 0.69 (0.53-0.91) | 0.97 |
| No | 66/1392 (5) | 97/1400 (7) | 0.69 (0.5-0.94) | |
| Abbreviations: CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; XAR, XARELTO. | ||||
Connolly et al (2018)38
| XAR+Aspirin, n/N (%) | Aspirin Alone, n/N (%) | Hazard Ratio (95% CI) | Interaction P-Value | |
|---|---|---|---|---|
| Composite Endpoint: CV death, stroke, or MI (primary efficacy endpoint) | ||||
| Yes | 155/3043 (5.1) | 212/3040 (7) | 0.72 (0.58-0.88) | 0.62 |
| No | 192/5270 (3.6) | 248/5221 (4.8) | 0.77 (0.64-0.93) | |
| Modified ISTH Major Bleeding | ||||
| Yes | 99/3043 (3.3) | 60/3040 (2) | 1.65 (1.2-2.27) | 0.95 |
| No | 164/5270 (3.1) | 98/5221 (1.9) | 1.67 (1.3-2.15) | |
| Abbreviations: CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; ISTH, International Society on Thrombosis and Hemostasis; MI, myocardial infarction; XAR, XARELTO. | ||||
Bhatt et al (2020)39
| XAR+Aspirin (n=9152) | Placebo+Aspirin (n=9126) | XAR+Aspirin vs Placebo+Aspirin | P-Value for Interactiona | ||||
|---|---|---|---|---|---|---|---|
| No. of First Events/Pts (%) | Kaplan-Meier Risk at 36 Months | No. of First Events/Pts (%) | Kaplan-Meier Risk at 36 Months | Hazard Ratio (95% CI) | P Value | ||
| Efficacy Outcomes | |||||||
| CV death, stroke, or MI | 0.77 | ||||||
| No diabetes at baseline | 200/5704 (3.5) | 5.8 | 257/5652 (4.5) | 7.2 | 0.77 (0.64-0.93) | 0.005 | |
| Diabetes at baseline | 179/3448 (5.2) | 8.4 | 239/3474 (6.9) | 10.7 | 0.74 (0.61-0.90) | 0.002 | |
| Death from any cause | 0.82 | ||||||
| No diabetes at baseline | 166/5704 (2.9) | 5.1 | 197/5652 (3.5) | 5.7 | 0.84 (0.68-1.03) | 0.09 | |
| Diabetes at baseline | 147/3448 (4.3) | 6.8 | 181/3474 (5.2) | 8.6 | 0.81 (0.65-1.00) | 0.05 | |
| Primary Safety Outcome | |||||||
| Major bleeding | 0.97 | ||||||
| No diabetes at baseline | 178/5704 (3.1) | 4.4 | 105/5652 (1.9) | 3.2 | 1.69 (1.33-2.15) | <0.0001 | |
| Diabetes at baseline | 110/3448 (3.2) | 4.5 | 65/3474 (1.9) | 3.4 | 1.7 (1.25-2.31) | 0.0006 | |
| Net Clinical Benefit Outcome | |||||||
| CV death, stroke, MI, fatal bleeding, or symptomatic bleeding into critical organ | 0.78 | ||||||
| No diabetes at baseline | 227/5704 (4.0) | 6.6 | 276/5652 (4.9) | 7.6 | 0.81 (0.68-0.97) | 0.02 | |
| Diabetes at baseline | 204/3448 (5.9) | 9.1 | 258/3474 (7.4) | 11.8 | 0.78 (0.65-0.94) | 0.01 | |
| Abbreviations: CI, confidence interval; CV, cardiovascular; MI, myocardial infarction; no., number; pts, patients; XAR, XARELTO. aTest of interaction of relative risk reduction (Cox regression). | |||||||
VOYAGER PAD was a phase 3, multicenter, randomized, placebo-controlled, double-blind, international study designed to evaluate whether XARELTO 2.5 mg twice daily plus aspirin 100 mg once daily is more effective than aspirin 100 mg once daily alone for the risk reduction of major atherothrombotic vascular outcomes consisting of both CV and limb events in patients with symptomatic PAD undergoing lower extremity revascularization (LER).13
| Baseline DM | XAR+Aspirin, n/N (%) | Aspirin Alone, n/N (%) | Hazard Ratio (95% CI) |
|---|---|---|---|
| Primary Efficacy Outcome: composite of ALI, major amputation of vascular etiology, MI, ischemic stroke, or CV death | |||
| Yes | 248/1313 (18.89) | 261/1316 (19.83) | 0.94 (0.79-1.11) |
| No | 260/1972 (13.18) | 323/1961 (16.47) | 0.79 (0.67-0.93) |
| Safety Outcome: Major bleeding according to TIMI classification | |||
| Yes | 31/1298 (2.39) | 13/1305 (1) | 2.45 (1.28-4.69) |
| No | 31/1958 (1.58) | 31/1942 (1.6) | 1.01 (0.61-1.66) |
| Abbreviations: ALI, acute limb ischemia; CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; MI, myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction; XAR, XARELTO. | |||
Low Wang et al (2021)41
Sharma et al (2023)15 conducted a post hoc analysis of the COMMANDER-HF study that compared the efficacy and safety of low-dose XARELTO in heart failure patients with sinus rhythm and coronary disease with diabetes vs without diabetes.
Arjunan et al (2026)17 conducted a real-world study at a tertiary care hospital in northern India from January 2022 to December 2023. The study enrolled 101 patients with PAD and T2DM who underwent lower limb revascularization by angioplasty, stenting, or bypass surgery.
| Outcome | n (%) |
|---|---|
| MALE | 62 (61.4) |
| Major amputation | 17 (16.8) |
| Minor amputation | 45 (44.6) |
| MACE | 34 (33.7) |
| CAD | 10 |
| CVA | 1 |
| Wound healed | 16 (15.8) |
| Abbreviations: CAD, coronary artery disease; CVA, cerebrovascular accident; MACE, major adverse cardiovascular event; MALE, major adverse limb event. | |
Salle et al (2026)18 conducted a prospective study using data from the XATOA (Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis) registry to assess the clinical characteristics and outcomes of patients with DM and CVD initiating DPI with XARELTO 2.5 mg twice daily plus aspirin in clinical practice. The registry enrolled patients with CAD and/or PAD.
Chen et al (2026)19 conducted a retrospective cohort study using data from the clinical database of Tri-Service General Hospital in northern Taiwan to compare the effectiveness and safety of XARELTO, apixaban, dabigatran, and edoxaban in patients with both DM and AF.
| Complication | XARELTO (n=175) | HR (95% CI) | P-Value |
|---|---|---|---|
| Total MACE | 12 | 0.65 (0.32-1.35) | 0.251 |
| Acute myocardial infarction | 3 | 0.68 (0.16-2.83) | 0.591 |
| Ischemic stroke | 6 | 0.52 (0.2-1.35) | 0.177 |
| Cardiovascular death | 3 | 2.58 (0.26-25.96) | 0.421 |
| Major bleeding events | 15 | 1.61 (0.72-3.6) | 0.242 |
| Intracranial hemorrhage | 4 | 4.42 (0.49-39.55) | 0.184 |
| Gastrointestinal bleeding | 11 | 1.22 (0.5-2.94) | 0.664 |
| All-cause mortality | 14 | 1.06 (0.49-2.28) | 0.878 |
| Note: HRs are based on comparisons with apixaban. Abbreviations: AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular event. | |||
Ruigómez et al (2024)20 conducted a study using healthcare databases from 4 European countries, Germany, the Netherlands, Sweden, and the UK, to evaluate the safety of XARELTO compared with VKAs in patients receiving treatment for and secondary prevention of VTE. The study also evaluated mortality risk and bleeding outcomes among XARELTO users according to older age, renal function, and diabetes.
| Outcome | Country | Events, n | Person-years | IR (95% CI) |
|---|---|---|---|---|
| Intracranial bleeding | UK (n=5680) | 0 | 493 | 0 |
| Netherlands (n=586) | 0 | 51 | N/A | |
| Germany (n=25,914) | 19 | 5776.4 | 0.33 (0.2-0.51) | |
| Sweden (n=12,557) | 7 | 798 | 0.88 (0.42-1.84) | |
| Gastrointestinal bleeding | UK (n=5680) | 4 | 490 | 0.81 (0.22-2.09) |
| Netherlands (n=586) | 0 | 49 | N/A | |
| Germany (n=25,914) | 96 | 5725.6 | 1.68 (1.36-2.05) | |
| Sweden (n=12,557) | 14 | 791 | 1.77 (1.05-2.99) | |
| Urogenital bleeding | UK (n=5680) | 2 | 488.2 | 0.41 (0.05-1.48) |
| Netherlands (n=586) | 0 | 49 | N/A | |
| Germany (n=25,914) | 33 | 5752.9 | 0.57 (0.39-0.81) | |
| Sweden (n=12,557) | 9 | 797 | 1.13 (0.59-2.17) | |
| Other bleeding | UK (n=5680) | 1 | 492 | 0.2 (0.01-1.13) |
| Netherlands (n=586) | 0 | 51 | N/A | |
| Germany (n=25,914) | 32 | 5754.4 | 0.56 (0.38-0.79) | |
| Sweden (n=12,557) | 4 | 797 | 0.5 (0.19-1.34) | |
| Mortality | UK (n=5680) | 30 | 493 | 6.08 (4.11-8.69) |
| Netherlands (n=586) | 1 | 49 | 2 (0-8.1) | |
| Germany (n=25,914) | 296 | 5782.9 | 5.12 (4.55-5.74) | |
| Sweden (n=12,557) | 41 | 799 | 5.13 (3.78-6.97) | |
| Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; IR, incidence rate; N/A, not available; UK, United Kingdom. | ||||
A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, Derwent® (and/or other resources, including internal/external databases) was conducted on 15 October 2026.
| 1 | Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). Am Heart J. 2015;170(4):675-682.e8. |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 | |
| 31 | |
| 32 | |
| 33 | |
| 34 | |
| 35 | |
| 36 | |
| 37 | |
| 38 | |
| 39 | |
| 40 | |
| 41 |
Would you like to clear and leave your conversation? Message history will be lost.